Should I buy or sell Achieve Life Sciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACHV shares. View ACHV analyst ratings or view top-rated stocks .

What is Achieve Life Sciences' stock price target for 2024?

3 analysts have issued twelve-month price objectives for Achieve Life Sciences' stock. Their ACHV share price targets range from $11.00 to $20.00. On average, they expect the company's stock price to reach $16.33 in the next year. This suggests a possible upside of 270.4% from the stock's current price. View analysts price targets for ACHV or view top-rated stocks among Wall Street analysts .

How have ACHV shares performed in 2024?

Achieve Life Sciences' stock was trading at $4.12 on January 1st, 2024. Since then, ACHV shares have increased by 7.0% and is now trading at $4.41. View the best growth stocks for 2024 here .

When is Achieve Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ACHV earnings forecast .

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) released its quarterly earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.07. During the same period in the previous year, the firm earned ($0.76) EPS.

What ETF holds Achieve Life Sciences' stock?

Simplify Propel Opportunities ETF holds 217,845 shares of ACHV stock, representing 0.94% of its portfolio.

When did Achieve Life Sciences' stock split?

Achieve Life Sciences shares reverse split on the morning of Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Gran Tierra Energy (GTE) , Bionano Genomics (BNGO) , Novan (NOVN) , Aeterna Zentaris (AEZS) , Zosano Pharma (ZSAN) , CNBX Pharmaceuticals (CNBX) , KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI) .

How do I buy shares of Achieve Life Sciences?

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ACHV

Achieve Life Sciences (ACHV) Stock Price, News & Analysis

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Free ACHV Stock Alerts

$4.46

+0.01 (+0.22%)

(As of 03:31 PM ET)

Compare

Today's Range: $4.39
▼
$4.58
50-Day Range: $3.82
▼
$4.67
52-Week Range: $3.03
▼
$10.30

Volume: 46,531 shs
Average Volume: 89,319 shs
Market Capitalization: $152.76 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.33

Get Achieve Life Sciences alerts:

Achieve Life Sciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 270.4% Upside
$16.33 Price Target
Short Interest: Bearish
2.09% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.94) to ($0.88) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.80 out of 5 stars

Medical Sector

646th out of 930 stocks

Diagnostic Substances Industry

8th out of 12 stocks

3.5

Analyst's Opinion

Consensus Rating
Achieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Achieve Life Sciences has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.09% of the outstanding shares of Achieve Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
Achieve Life Sciences has a short interest ratio ("days to cover") of 7.6.
Change versus previous month
Short interest in Achieve Life Sciences has recently increased by 2.24%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Achieve Life Sciences does not currently pay a dividend.
Dividend Growth
Achieve Life Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACHV.

3.8

News and Social Media Coverage

News Sentiment
Achieve Life Sciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Achieve Life Sciences this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for ACHV on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Achieve Life Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Achieve Life Sciences is held by insiders.
Percentage Held by Institutions
Only 33.52% of the stock of Achieve Life Sciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Achieve Life Sciences are expected to grow in the coming year, from ($0.94) to ($0.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Achieve Life Sciences is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Achieve Life Sciences is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About Achieve Life Sciences Stock (NASDAQ:ACHV)

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.

ACHV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACHV Stock News Headlines

April 13, 2024 | msn.com

McNair rolls past College Achieve Paterson - Softball recap

April 11, 2024 | finance.yahoo.com

Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 9, 2024 | americanbankingnews.com

Achieve Life Sciences (NASDAQ:ACHV) Share Price Passes Above 200 Day Moving Average of $4.40

April 4, 2024 | seekingalpha.com

Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns

April 1, 2024 | finance.yahoo.com

ACHV: 2023 Results

March 30, 2024 | seekingalpha.com

Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript

March 29, 2024 | finance.yahoo.com

Q4 2023 Achieve Life Sciences Inc Earnings Call

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 28, 2024 | benzinga.com

Recap: Achieve Life Sciences Q4 Earnings

March 28, 2024 | finance.yahoo.com

Achieve Life Sciences Inc Reports Year-End Loss, Progresses Towards FDA Approval

March 28, 2024 | globenewswire.com

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update

March 28, 2024 | msn.com

Options Volatility and Implied Earnings Moves Today, March 28, 2024

March 27, 2024 | msn.com

Achieve Life Sciences Q4 2023 Earnings Preview

March 20, 2024 | finance.yahoo.com

Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

March 18, 2024 | bizjournals.com

Over $1 million raised for community initiatives, scholarships at Donald Driver's Driven To Achieve Awards: Slideshow

March 16, 2024 | ca.finance.yahoo.com

ACHV Apr 2024 2.500 call

March 14, 2024 | finance.yahoo.com

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024

March 11, 2024 | msn.com

How AI Is Saving Lives

March 11, 2024 | nj.com

WATCH: No. 12 College Achieve Asbury Park celebrates winning the Group 1 state title

March 11, 2024 | msn.com

Luka Doncic Creates NBA History; Becomes the First Player to Achieve THIS Feat

March 10, 2024 | msn.com

No. 12 College Achieve Asbury Park owns Group 1, easily wins title in 1st year

March 8, 2024 | finance.yahoo.com

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

March 6, 2024 | globenewswire.com

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

March 1, 2024 | finance.yahoo.com

ACHV: ORCA-OL to Start 2Q:24

February 29, 2024 | markets.businessinsider.com

Buy Rating for Achieve Life Sciences on Cytisinicline’s Promising Future and Solid Financials

February 29, 2024 | msn.com

Achieve Life Sciences stock falls 11% amid FDA update, securities sale

See More Headlines

Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/16/2023
Today: 4/16/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Diagnostic substances
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:ACHV
CUSIP: 68230A10
CIK: 949858
Web: achievelifesciences.com
Phone: (604) 210-2217
Fax: 425-686-1600
Employees: 20
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.33
High Stock Price Target: $20.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +267.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,820,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -936.70%
Return on Assets: -127.66%

Debt

Debt-to-Equity Ratio: 4.02
Current Ratio: 0.82
Quick Ratio: 0.82

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.07) per share
Price / Book: -63.57

Miscellaneous

Outstanding Shares: 34,250,000
Free Float: 33,567,000
Market Cap: $152.41 million
Optionable: Optionable
Beta: 1.32

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Richard A. B. Stewart (Age 65)
Executive Chairman
Comp: $575k
Mr. John A. Bencich M.B.A. (Age 47)
CEO & Director
Comp: $733.12k
Dr. Cindy Jacobs M.D. (Age 66)
Ph.D., President, Chief Medical Officer & Director
Comp: $614.25k
Mr. Jerry Wan (Age 42)
Principal Accounting Officer
Dr. Anthony Clarke (Age 68)
Chief Scientific Officer
Comp: $546k
Ms. Jaime Xinos
Executive Vice President of Commercial

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACHV Stock Analysis - Frequently Asked Questions

Should I buy or sell Achieve Life Sciences stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings or view top-rated stocks.
What is Achieve Life Sciences' stock price target for 2024?: 3 analysts have issued twelve-month price objectives for Achieve Life Sciences' stock. Their ACHV share price targets range from $11.00 to $20.00. On average, they expect the company's stock price to reach $16.33 in the next year. This suggests a possible upside of 270.4% from the stock's current price.
View analysts price targets for ACHV or view top-rated stocks among Wall Street analysts.
How have ACHV shares performed in 2024?: Achieve Life Sciences' stock was trading at $4.12 on January 1st, 2024. Since then, ACHV shares have increased by 7.0% and is now trading at $4.41.
View the best growth stocks for 2024 here.
When is Achieve Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ACHV earnings forecast.
How were Achieve Life Sciences' earnings last quarter?: Achieve Life Sciences, Inc. (NASDAQ:ACHV) released its quarterly earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.07. During the same period in the previous year, the firm earned ($0.76) EPS.

What ETF holds Achieve Life Sciences' stock?: Simplify Propel Opportunities ETF holds 217,845 shares of ACHV stock, representing 0.94% of its portfolio.
When did Achieve Life Sciences' stock split?: Achieve Life Sciences shares reverse split on the morning of Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Achieve Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).
How do I buy shares of Achieve Life Sciences?: Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACHV) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial